Background
==========

We have reported a pilot study of ABM-MCT to areas of ischemic myocardium \[[@B1]\], and in humans at 8 weeks follow-up after ABM-MCT ACC\'03. The purpose of this study was to assess whether the changes in the QOL in patients with end-stage ischemic heart failure (ESIHF) submitted to catheter-based ABM-MCT persists in the 6 month follow-up.

Methods
=======

A prospective assessment of the QOL before and 8 and 24 weeks after ABM-MCT guided by the NOGA system, targeting hibernating myocardium in ESIHF, using the Minnesota Living with Heart Failure Questionnaire and the Medical Outcomes Study Short Form-36. The cardiac evaluation included Canadian Cardiovascular Society class, VO~2~max on the treadmill test, ejection fraction and end systolic volume on two-dimensional echocardiogram and total reversibility defect on MIBI-SPECT.

Results
=======

There were 14 patients (two females). The changes in parameters 8 and 24 weeks after the procedure are presented in Table [1](#T1){ref-type="table"}. According to these objective data we observed a QOL improvement, based on the scores of Minnessota varying from 46 ± 19 to 30 ± 17 (*P*= 0.002) at 8 weeks and to 18 ± 14 (*P*= 0.003) at 24 weeks, and an increase of all eight dimensions of the Medical Outcomes Study Short Form-36 as presented in Table [2](#T2){ref-type="table"}.

                                          Baseline       8 weeks       *P*      24 weeks     *P*
  --------------------------------------- -------------- ------------- -------- ------------ -------
  Canadian Cardiovascular Society class   2.64 ± 0.84    1.28 ± 0.61   0.0001   1.44 ± 0.5   0.003
  Ejection fraction                       30 ± 5         35 ± 8        0.029    32.4 ± 6     0.04
  End systolic volume                     147 ± 53       123 ± 48      0.02     139 ± 49     0.01
  VO~2~max                                17.96 ± 8.78   23.4 ± 8      0.01     24.4 ± 8     0.05
  Total reversibility defect              15 ± 14        4.5 ± 10      0.02                  

  Medical Outcomes Study Short Form-36   Baseline   8 weeks   *P*      24 weeks   *P*
  -------------------------------------- ---------- --------- -------- ---------- ------
  BP                                     39 ± 22    79 ± 27   0.0014   68 ± 30    0.03
  MH                                     58 ± 21    74 ± 19   0.02     77 ± 20    0.02
  GH                                     61 ± 19    77 ± 16   0.03     81 ± 21    0.05
  PF                                     43 ± 26    68 ± 24   0.009    71 ± 26    0.03
  RE                                     39 ± 49    58 ± 43   0.27     92 ± 15    0.06
  RP                                     35 ± 42    65 ± 42   0.03     84 ± 27    0.06
  SF                                     68 ± 26    74 ± 21   0.34     86 ± 14    0.04
  VI                                     57 ± 22    74 ± 18   0.02     76 ± 19    0.08

Conclusion
==========

The data suggest that ABM-MCT can improve the QOL of patients with ESIHF. Prospective studies with a greater number of patients will be necessary to confirm these initial data.
